晚期/转移性乳腺癌的老年患者中的Palbociclib:一个系统性审查
Etienne Brain1, Connie Chen2, Sofia Simon3
1Department of Medical Oncology, Institut Curie/Saint-Cloud, Paris, France.
Targeted oncology
|March 28, 2024
概括
帕尔博西克利布对晚期HR+/HER2-乳腺癌的老年妇女有效,保持生活质量. 现实世界的研究证实了在这个人群中临床试验的结果.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
背景情况:
- 与内分泌疗法结合的Palbociclib已被批准用于HR+/HER2-高级乳腺癌.
- 老年女性代表着乳腺癌日益增长的人口统计数据,但在临床试验中通常代表性不足.
研究的目的:
- 系统地审查HR+/HER2-晚期/转移性乳腺癌 (a/mBC) 的老年患者的Palbociclib治疗结果.
- 整合随机对照试验 (RCT) 和现实研究 (RWE) 的证据,分析palbociclib在老年患者中的有效性和安全性.
主要方法:
- 在PubMed,EMBASE和Cochrane图书馆进行了系统的文献搜索,截至2023年5月4日.
- 包括52篇独特文章:13篇来自RCT和39篇来自RWE研究,分析了老年患者群体 (通常≥65岁) 的palbociclib结果.
主要成果:
- 在RCT和RWE研究中,Palbociclib在老年患者和年轻患者中表现出类似的疗效 (无进展生存率,总生存率,反应率) 和安全性.
- 在接受palbociclib的老年患者中,生活质量得到维持.
- 虽然老年患者的剂量修改,减少和中止率较高,但这些并没有对疗效产生负面影响.
结论:
- 帕尔博西克利布在HR+/HER2-a/mBC的老年患者中有效且耐受性良好,维持生活质量.
- 现实世界的证据支持palbociclib在老年患者的疗效和耐受性,与临床试验的发现一致.
相关概念视频
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K